Cervical cancer screening kit

A kit and cervical cancer technology, applied in measuring devices, instruments, disease diagnosis, etc., can solve the problems of unseen SPARCL1 and cervical cancer reports, and achieve good clinical application prospects, less trauma, and less side effects

Active Publication Date: 2017-06-09
成都医学院第一附属医院
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] There is no report on the relationship between SPARCL1 and cervical cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cervical cancer screening kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Example 1 The relationship between the expression level of SPARCL1 (SPARCL1) and cervical cancer

[0021] 1. Experimental method

[0022] 1. Sample

[0023] The serum samples collected and experiments performed in this study were approved by the Ethics Committee of the First Affiliated Hospital of Chengdu Medical College according to the guidelines. Blood was collected from patients before the first surgery and before any treatment.

[0024] 2. Detection method of SPARCL1 (SPARCL1) expression level in blood

[0025] 2.1 Blood separation

[0026] Extract the blood of clinical patients and healthy controls, centrifuge after EDTA anticoagulation (1200rpm, 10min), absorb the supernatant and perform a second centrifugation (3000rpm, 15min), absorb the supernatant and store it at -80°C;

[0027] 2.2 ELISA detection

[0028] SPARCL1 levels in serum were measured and quantified using an ELISA kit (KITZOME, Shenzhen, China) according to the manufacturer's instructions. Eac...

Embodiment 2

[0046] Embodiment 2 Composition and method of use of the kit for detecting blood SPARCL1 (SPARCL1) of the present invention

[0047] 1. ELISA detection kit

[0048] 1. The composition of the kit

[0049] Detection kit (50 copies):

[0050] components volume Capture antibody 5ml (4.0ug / ml) Standard (SPARCL1 standard) 2ml (12000pg / ml) Detection antibody 5ml (100ng / ml) ELISA (Streptavidin-HRP) 25ul (1:200 dilution) Substrate solution 5ml Stop solution 2.5ml Wash buffer 200ml Reagent diluent 50ml

[0051] 2. How to use the kit

[0052]Extract the blood of the sample to be tested, centrifuge after EDTA anticoagulation (1200rpm, 10min), absorb the supernatant and perform a second centrifugation (3000rpm, 15min), absorb the supernatant, and use the following method to detect the expression level of SPARCL1 (SPARCL1):

[0053] 2.1 Adding samples: Set up blank wells, standard wells, and sample wells to be tested res...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a cervical cancer screening kit, comprising an optional reagent to detect expression level of SPARCL1 in blood. The invention also discloses the application of the reagent to detect the expression level of SPARCL1 in blood, in the preparation of cervical cancer screening reagents. The cervical cancer screening kit can effectively judge the risk of people under test to suffer cercal cancer by detecting the expression level of SPARCL1, is applicable to the clinical assisted diagnosis of cervical cancer, provides effective basis for taking related treatment measures or making decisions for patients, and has a good clinical application prospect.

Description

technical field [0001] The invention relates to a screening kit for cervical cancer. Background technique [0002] Cervical cancer is the second most common malignant tumor in women, second only to breast cancer in incidence. Every year, there are more than 1.5 million new cases of cervical cancer, and more than 300,000 people die from cervical cancer. Cervical cancer is caused by persistent infection with the oncogenic human papillomavirus (HPV). While HPV infection is an integral factor, it is not sufficient to cause cancer. Most low-grade precursor lesions from acute HPV infection clear spontaneously in more than 90% of cases within a few months, and less than 10% of cases eventually progress to high-grade lesions or invasive carcinoma. Cervical intraepithelial neoplasia is a definite precancerous lesion of the cervix, and during the evolution from precancerous lesions to malignant tumors, the expression of various oncogenes and invasion-related genes is obviously abnor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/574
CPCG01N33/57411G01N2333/46G01N2800/36
Inventor 许颖吴东明张涛杨菁
Owner 成都医学院第一附属医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap